Navigation Links
Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Date:11/13/2008

ulated in part by the level and activity of testosterone. TRELSTAR(R) is currently available in a 4-week depot formulation (TRELSTAR(R) DEPOT) and a 12-week long-acting formulation (TRELSTAR(R) LA), offering an alternative treatment for prostate cancer when orchiectomy (removal of the testicles) or estrogen administration are either not indicated or unacceptable to the patient. TRELSTAR(R) does not require refrigeration and should be stored at controlled room temperature.

Important Safety Information

In clinical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of anaphylactic shock and angioedema have been reported. TRELSTAR(R) is contraindicated for use in women.

About Prostate Cancer

Prostate cancer is the most common cancer in men in the U.S., excluding skin cancer, and is estimated to account for 25 percent of all new cancers diagnosed in men. According to the American Cancer Society, approximately 186,320 new cases of prostate cancer are expected to be diagnosed in 2008 in the U.S.; 28,660 men with prostate cancer are expected to die this year(1). The majority of cases diagnosed are in men over the age of 65. Prostate cancer can be detected early through regular digital rectal examinations and PSA testing. Low PSA levels typically are found in the blood of healthy men; the amount of PSA in the blood normally increases in the presence of prostate cancer.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product de
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine news :

1. Watson Pharmaceuticals Reports Third Quarter 2008 Results
2. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
3. Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds
4. Watson Wyatt Identifies Trends for Benefits Open Enrollment Season
5. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
6. Watson Announces Limited Recall of Fentanyl Transdermal System
7. Watson Launches Omeprazole Delayed-Release Capsules, 40MG
8. Chantix Blamed for Suicide in Lawsuit Against Pfizer Filed by Cory Watson Crowder & DeGaris
9. Watson Launches Generic MARINOL(R) Capsules
10. Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
11. Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 18, 2013) There are significant cost and ... to diagnose or treat gastrointestinal problems, according to ... , A study by New York Presbyterian Hospital ... testing may substantially reduce the cost and risk ... is believed to affect nearly 25 percent of ...
(Date:5/18/2013)... 18, 2013 Today, Zane Benefits, ... agents’ role in Marketplaces . Zane Benefits, which ... sponsored health benefits, is the leader in health ... health reimbursement arrangements . , According to Zane ... Services (HHS) recently released a much-anticipated statement and ...
(Date:5/18/2013)... York, NY (PRWEB) May 18, 2013 After ... consistent efforts, SizeItUp formally announced the integration of ... redesigned 2012 Hyundai Genesis is set to stun the automobile ... and style. 2012 Hyundai Genesis is marked as the latest ... and heads the vehicles lined up for the year 2013. ...
(Date:5/18/2013)... Although obesity is associated with an increased risk ... esophageal adenocarcinoma, a type of esophageal cancer, is stronger ... on Cancer.gov, last reviewed in January 2012, overweight ... those of normal and healthy weight to develop this ... cancer is not well understood, it is now thought ...
(Date:5/18/2013)... Show And Go Training, the culmination of Eric ... that is all about is getting results in the fastest ... http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting an investigative review. , ... phase system” designed to make you faster, stronger, fitter and ... out in the gym. The training manual and exercise video ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced that it presented at the William Blair ... on October 3, 2007, at the New York,Palace Hotel ... the VNUS presentation webcast is available on the,corporate website ...
... SAN DIEGO, Oct. 3 Anadys Pharmaceuticals,Inc. (Nasdaq: ... BIO,InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 ... at The Palace Hotel in San,Francisco. Steve Worland, ... will present an overview of Anadys and an update ...
... A new Web site from Northwood,Health Systems has ... a five-year development effort in partnership with the best,Web ... perfect the,application of Web site technology," Northwood President and ... http://www.NorthwoodHealth.com, offers more than 1,000 accredited,continuing education courses ...
... NORCROSS, Ga., Oct. 3 Immucor, Inc. (Nasdaq:,BLUD), ... to,the blood transfusion industry, today reported financial results ... Revenue for the fiscal first quarter was ... in the same period last year. Of the ...
... Oct. 3 The patent lawsuit,by VNUS(R) Medical Technologies, ... Diomed, AngioDynamics and Vascular Solutions,is set to proceed to ... by both sides. In its motions VNUS had asked ... infringed the VNUS patents,while the defendants countered with their ...
... will work, experts say , WEDNESDAY, Oct. 3 (HealthDay ... help doctors determine the best chemotherapy for patients, U.S. ... tumors would be most likely to respond to standard ... has traditionally been a second-line therapy, based on gene ...
Cached Medicine News:Health News:Anadys Pharmaceuticals to Present at BIO InvestorForum 2007 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 3Health News:Immucor Announces Record Fiscal First Quarter Revenues 4Health News:Immucor Announces Record Fiscal First Quarter Revenues 5Health News:Immucor Announces Record Fiscal First Quarter Revenues 6Health News:Immucor Announces Record Fiscal First Quarter Revenues 7Health News:Immucor Announces Record Fiscal First Quarter Revenues 8Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 2Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 3Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ... SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting and ... will be held at the San Diego ... California , from May 20 - 22.  ... analytical system, incorporating commercial audio-visual technologies into new and ...
(Date:5/17/2013)... 17, 2013  ConvaTec today announced that it will report its 2013 ... , CEO, and Ed Borkowski , CFO, will ... telephone. To participate in the conference call within the ... To participate in the conference call outside the U.S. and ... is 72195398. Participants should dial in 10 minutes prior to ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
AchilloTrain is a comfortable knitted support with a silicone insert alongside the Achilles tendon and under the heel. An additional heel cushion is provided for the unaffected foot. It is worn to tr...
DarcoGel™ Upper chamber is foam filled, conforms to calf; gel-filled lower chamber molds to the malleoli for a custom fit. Freeze the removable liner for cold therapy. One size. Fits left or ri...
... maintaining the ankle in functional alignment. Entire ... cushioning AliPlast™ foam liner. The cushioning air ... heel in a protective hammock, reducing ulceration ... bed from side-lying to supine. Only the ...
Medicine Products: